<code id='AD9122D20B'></code><style id='AD9122D20B'></style>
    • <acronym id='AD9122D20B'></acronym>
      <center id='AD9122D20B'><center id='AD9122D20B'><tfoot id='AD9122D20B'></tfoot></center><abbr id='AD9122D20B'><dir id='AD9122D20B'><tfoot id='AD9122D20B'></tfoot><noframes id='AD9122D20B'>

    • <optgroup id='AD9122D20B'><strike id='AD9122D20B'><sup id='AD9122D20B'></sup></strike><code id='AD9122D20B'></code></optgroup>
        1. <b id='AD9122D20B'><label id='AD9122D20B'><select id='AD9122D20B'><dt id='AD9122D20B'><span id='AD9122D20B'></span></dt></select></label></b><u id='AD9122D20B'></u>
          <i id='AD9122D20B'><strike id='AD9122D20B'><tt id='AD9122D20B'><pre id='AD9122D20B'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:leisure time    Page View:1822

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In